<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Comprehensive adult medical eye evaluation.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American Academy of Ophthalmology Preferred Practice Patterns Committee. Comprehensive adult medical eye evaluation. San Francisco (CA): American Academy of Ophthalmology; 2010. 23 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Preferred Practice Patterns Committee. Comprehensive adult medical eye evaluation. San Francisco (CA): American Academy of Ophthalmology (AAO); 2005. 15 p. (Preferred practice pattern). [76 references]&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All Preferred Practice Patterns are reviewed by their parent panel annually or earlier if developments warrant and updated accordingly. To ensure that all Preferred Practice Patterns are current, each is valid for 5 years from the &quot;approved by&quot; date unless superseded by a revision.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Chronic angle-closure glaucoma  (365.23); Disorder of eye, unspecified  (360.9); Disorder of eye, unspecified  (379.90); Eye examination, not otherwise specified  (95.09); Macular degeneration (senile), unspecified  (362.50); Moderate nonproliferative diabetic retinopathy  (362.05); Nonexudative senile macular degeneration  (362.51); Ocular motility study  (95.15); Open-angle glaucoma, unspecified  (365.10); Open-angle glaucoma, unspecified  (365.13); Ophthalmoscopy  (16.21); Primary open angle glaucoma  (365.11); Proliferative diabetic retinopathy  (362.02); Severe nonproliferative diabetic retinopathy  (362.06); Unspecified cataract  (366.9); Unspecified glaucoma  (365.9); Visual field study  (95.05)"/><FieldValue Value="MSH: Cataract ; Diabetic Retinopathy ; Eye Diseases ; Glaucoma ; Glaucoma, Angle-Closure ; Glaucoma, Open-Angle ; Intraocular Pressure ; Macular Degeneration ; Medical History Taking ; Ophthalmoscopes ; Ophthalmoscopy ; Retinoscopy ; Slit Lamp ; Tonometry, Ocular ; Vision Screening ; Visual Acuity ; Visual Field Tests ; Visual Fields "/><FieldValue Value="MTH: Age related macular degeneration ; Anatomical narrow angle glaucoma ; Angle Closure Glaucoma ; Cataract ; Diabetic Retinopathy ; Disorder of eye ; Glaucoma ; Glaucoma, Open-Angle ; Intraocular pressure test ; Macular degeneration ; Ophthalmic examination and evaluation ; Ophthalmoscopy ; Physiologic Intraocular Pressure ; Proliferative diabetic retinopathy ; Retinoscopy ; Severe nonproliferative diabetic retinopathy ; Slit lamp biomicroscope (physical object) ; Slit lamp biomicroscopy (procedure) ; Tonometer ; Visual Acuity ; Visual field study ; Visual Fields "/><FieldValue Value="SNOMEDCT_US: Age related macular degeneration  (267718000); Angle-closure glaucoma  (392291006); Cataract  (128306009); Cataract  (193570009); Cataract  (247053007); Chronic angle-closure glaucoma  (33647009); Degenerative disorder of macula  (422338006); Diabetic retinopathy  (4855003); Disorder of eye  (371405004); Disorder of eye  (371409005); Glaucoma  (23986001); Intraocular pressure  (41633001); Intraocular pressure test  (252832004); Moderate nonproliferative diabetic retinopathy  (312904009); Nonexudative age-related macular degeneration  (414875008); Ocular motility study  (17259005); Ocular photography for medical evaluation and documentation, stereophotography  (21685006); Open-angle glaucoma  (46168003); Open-angle glaucoma  (84494001); Ophthalmic examination and evaluation  (36228007); Ophthalmoscope  (309640002); Ophthalmoscopy  (53524009); Primary open angle glaucoma  (77075001); Proliferative diabetic retinopathy  (59276001); Retinoscopy  (397524001); Severe nonproliferative diabetic retinopathy  (312905005); Slit lamp biomicroscope  (397247004); Slit lamp biomicroscopy  (398891008); Slit lamp biomicroscopy  (55468007); Slit lamp fundus examination  (410455004); Tonometer  (391932009); Vision screening  (408760009); Visual acuity  (363983007); Visual acuity testing  (16830007); Visual field  (73750009); Visual field study  (86944008)"/><FieldValue Value="UMD: Ophthalmic Tonometers  (16-809); Ophthalmoscopes  (12-815); Slit Lamps  (12-281)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Ocular diseases, including&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Open-angle glaucoma &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Primary angle-closure glaucoma &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diabetic mellitus &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Age-related macular degeneration &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cataract &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Screening" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Ophthalmology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Health Plans" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To provide recommendations concerning the comprehensive adult medical eye evaluation with the following clinical objectives:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Detect and diagnose ocular abnormalities and diseases &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Identify risk factors for ocular disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Identify risk factors for systemic disease based on ocular findings &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Establish the presence or absence of ocular signs or symptoms of systemic disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Determine the refractive and health status of the eye, visual system, and related structures &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Discuss the results and implications of the examination with the patient &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Initiate an appropriate management plan (e.g., determine frequency of future visits, further diagnostic tests, referral, or treatment as indicated) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adults without known ocular conditions or risk factors, or with previously identified conditions or risk factors, or with recurrent or new symptoms&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Comprehensive ophthalmologic evaluation, including patient history and ocular examination&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Visual function&lt;/li&gt;&#xA;    &lt;li&gt;Social and psychological dimensions of quality of life, mobility, and physical function&lt;/li&gt;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Literature searches to update the Preferred Practice Patterns (PPP) were undertaken in February and August 2010 and retrieved 1128 citations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Searches for Comprehensive Adult Eye Evaluations PPP Revisions 2010 in PubMed database&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&quot;activities of daily living&quot; [MeSH Terms] AND (&quot;vision disorders&quot; [MeSH Terms] OR &quot;visual acuity&quot; [MeSH Terms] OR &quot;visual fields&quot; [MeSH Terms] OR &quot;visually impaired persons&quot; [MeSH Terms]). Limits: English, Publication Date from 2004. Retrieved 240 citations. February 24, 2010. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&quot;quality of life&quot; [MeSH Terms] AND (&quot;vision disorders&quot; [MeSH Terms] OR &quot;visual acuity&quot; [MeSH Terms] OR &quot;visual fields&quot; [MeSH Terms] OR &quot;visually impaired persons&quot; [MeSH Terms]) Limits: English, Publication Date from 2004. Retrieved 434 citations. February 24, 2010. 355 unique citations. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;(&quot;diagnosis&quot; [MeSH Terms]) AND &quot;vision disorders&quot; [MeSH Terms]. Limits: Clinical Trial, Practice Guideline, English, Publication Date from 2004. Retrieved 457 citations. February 24, 2010. 412 unique citations.&#xD;&#xA;    &lt;p&gt;Total unique citations = 1007&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;89 possibly relevant sent to PPP Committee Feb 25, 2010&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Socioeconomic information: Limits: Adult, English, Human, Publication Date from 2004. Searched for related citations to PMID 17420375 (Frick KD, Gower EW, Kempen JH, Wolff JL. Economic impact of visual impairment and blindness in the United States. Arch Ophthalmol 2007;125:544-50, which was retrieved in earlier searches). Retrieved 121 unique citations. August 2, 2010. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;Economic searches = 5 reviewed in full text &amp;amp; used.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;No new studies were identified for use in the recommendations for care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;From the literature searches, 20 studies were identified for use in the Background or Socioeconomic Sections: Quality of life = 15, Socioeconomic = 5 &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;References from the Age-Related Macular Degeneration (2008), Diabetic Retinopathy (2008), Primary Angle Closure (2010), and Primary Open-Angle Glaucoma (2010) PPPs were used to update the Prevalence/Incidence and Risk Factors sections &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;4 additional prevalence/incidence studies (Reference numbers 8, 30, 75, 103 in the original guideline document) were identified by an author &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;1 additional prevalence/incidence study was identified through surveillance of literature (Reference number 86 Zhang et al JAMA 2010) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A total of 25 new studies were included in the update:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Quality of life - 15 studies&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Economic impact - 5 studies&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Prevalence/incidence - 5 studies&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To rate individual studies, a scale based on the Scottish Intercollegiate Guideline Network* (SIGN) is used. The definitions and levels of evidence to rate individual studies are as follows:&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Rating Scheme for the Strength of Evidence&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;I++&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with a very low risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;I+&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;I-&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;II++&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High quality systematic reviews of case control or cohort studies&lt;br /&gt;&#xD;&#xA;            High quality case-control or cohort studies with a very low risk of confounding or bias and a moderate probability that the relationship is causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;II+&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well conducted case-control or cohort studies with a low risk of confounding or bias and a high probability that the relationship is causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;II-&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;III&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Non-analytic studies (e.g., case reports, case series)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Scottish Intercollegiate Guidelines Network. SIGN 50: a guideline developer's handbook. Available at &lt;a href=&quot;http://www.sign.ac.uk/methodology/index.html&quot; title=&quot;SIGN Web site&quot;&gt;www.sign.ac.uk/methodology/index.html&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendations for care are formed based on the body of the evidence. The body of evidence quality ratings are defined by GRADE* as follows:&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Body of Evidence Quality Ratings&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Good quality&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is very unlikely to change the confidence in the estimate of effect.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Moderate quality&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is likely to have an important impact on the confidence in the estimate of effect and may change the estimate.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Insufficient quality&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is very likely to have an important impact on the confidence in the estimate of effect and is likely to change the estimate. Any estimate of effect is very uncertain.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 208;336:924-6.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Preferred Practice Pattern&lt;sup&gt;&amp;reg;&lt;/sup&gt; (PPP) guidelines should be clinically relevant and specific enough to provide useful information to practitioners. Where evidence exists to support a recommendation for care, the recommendation should be given an explicit rating that shows the strength of evidence. To accomplish these aims, methods from the Scottish Intercollegiate Guidelines Network (SIGN) and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) group are used. GRADE is a systematic approach to grading the strength of the total body of evidence that is available to support recommendations on a specific clinical management issue. Organizations that have adopted GRADE include SIGN, the World Health Organization, the Agency for Healthcare Research and Policy, and the American College of Physicians.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Key recommendations for care are defined by GRADE* as follows:&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: GRADE Recommendations&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Strong recommendation&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Used when the desirable effects of an intervention clearly outweigh the undesirable effects or clearly do not.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Discretionary recommendation&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Used when the trade-offs are less certain--either because of low quality evidence or because evidence suggests that desirable and undesirable effects are closely balanced.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 208;336:924-6.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Regular examinations, coupled with appropriate medical and laser treatment for those who require it, have been shown to be extremely cost-effective in the diabetic population, particularly when compared with disability payments for those who would otherwise become blind.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Socioeconomic Considerations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In 2006, the societal cost of major visual disorders (age-related macular degeneration [AMD], cataract, diabetic retinopathy, primary open-angle glaucoma [POAG], refractive errors) among U.S. residents 40 and older was estimated to be $35.4 billion. This total comprised $16.2 billion in direct medical costs, $11.1 billion in other direct costs, and $8 billion in productivity losses. These costs do not include associated comorbid conditions such as depression or injury.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In another study, U.S. residents 40 and older with blindness or visual impairment had estimated excess medical expenditures of $5.1 billion. This estimate includes the cost of home care and informal care for blind and visually impaired adults. The study also estimated that the total number of quality adjusted life years lost for individuals with blindness or visual impairment was 209,000. Valuing each year lost at $50,000 would add $10.4 billion to this estimate of the annual economic impact of visual impairment and blindness.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In Australia, researchers estimated that the economic impact and cost in 2004 was A$9.85 billion (&amp;asymp; US$7.02 billion), with vision disorders ranking seventh in the direct health care costs of various health conditions. Vision loss was also the seventh leading cause of disability in Australia, with the years of life lost to disability valued at A$4.8 billion (&amp;asymp; US$3.42 billion) annually.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In 2006, the annual nonmedical costs related to visual impairment in four European countries (France, Germany, Italy, and the United Kingdom) were estimated at &amp;euro;10,749 million (&amp;asymp; US$13,712 million) in France, &amp;euro;9,214 million (&amp;asymp; US$11,754 million) in Germany, &amp;euro;12,069 million (&amp;asymp; US$15,396 million) in Italy and &amp;euro;15,180 million (&amp;asymp; US$19,364 million) in the United Kingdom.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;These guidelines were reviewed by Council and approved by the Board of Trustees of the American Academy of Ophthalmology on September 11, 2010.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Ratings of the strength of recommendations (strong, discretionary) and quality ratings for the body of evidence (good, moderate, insufficient) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A comprehensive medical eye evaluation includes a history, examination, diagnosis, and initiation of management. Included within each part of the evaluation is a series of items particularly effective for the detection, diagnosis, and choice of appropriate therapy for refractive error, ocular disease, and systemic disease. The items listed are basic areas of evaluation or investigation and are not meant to exclude additional elements when appropriate. For example, because history taking is an interactive process, the patient's responses may guide the clinician to pursue additional questions and evaluation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;History&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In general, a thorough history may include the following items, although the exact composition varies with the patient's particular problems and needs.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Demographic data (e.g., name, date of birth, gender and where appropriate, ethnicity or race) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The identity of the patient's other pertinent health care providers &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Chief complaint and history of present illness &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Present status of visual function (e.g., patient's self-assessment of visual status, visual needs, any recent or current visual symptoms, and use of eyeglasses or contact lenses) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ocular symptoms (e.g., eyelid swelling, diplopia, redness, photophobia) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ocular history (e.g., prior eye disease, injuries, surgery, including cosmetic eyelid and refractive surgery, or other treatments and medications) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Systemic history: pertinent medical conditions and previous surgery &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Medications: ophthalmic and systemic medications currently used, including nutritional supplements &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Allergies or adverse reactions to medications &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Family history: pertinent familial ocular and systemic disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Social history (e.g., occupation; tobacco, alcohol, recreational drug use; family and living situation as appropriate) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Directed review of systems &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Ocular Examination&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The comprehensive eye examination consists of an evaluation of the physiologic function and the anatomic status of the eye, visual system, and its related structures. This usually includes the following elements:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Visual acuity with current correction (the power of the present correction recorded) at distance and, when appropriate, at near &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Measurement of current corrected visual acuity (with refraction when indicated) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Visual fields by confrontation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;External examination (e.g., eyelid position and character, lashes, lacrimal apparatus and tear function; globe position; and pertinent facial features) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pupillary function (e.g., size and response to light, relative afferent pupillary defect) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ocular alignment and motility &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Slit-lamp biomicroscopic examination: eyelid margins and lashes; tear film; conjunctiva; sclera; cornea; anterior chamber; and assessment of central and peripheral anterior chamber depth, iris, lens, and anterior vitreous &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Intraocular pressure measurement preferably with a contact applanation method (typically a Goldmann tonometer); contact tonometry may be deferred in the setting of suspected ocular infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fundus examination: mid and posterior vitreous, retina (including posterior pole and periphery), vasculature, and optic nerve &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of relevant aspects of patient's mental and physical status &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Examination of anterior segment structures routinely involves gross and biomicroscopic evaluation prior to and after dilation. Evaluation of structures situated posterior to the iris&amp;nbsp;is best performed through a dilated pupil. Optimal examination of the peripheral retina requires the use of the indirect ophthalmoscope or slit-lamp fundus biomicroscopy. Optimal examination of the macula and optic nerve requires the use of the slit-lamp biomicroscope and accessory diagnostic lenses.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Based on the patient's history and findings, additional tests or evaluations might be indicated to evaluate further a particular structure or function. These are not routinely part of the comprehensive medical eye clinical evaluation. Specialized clinical evaluation may include the following:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Monocular near-vision testing &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Potential acuity testing &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Glare testing &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Contrast sensitivity testing &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Color-vision testing &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Testing of stereoacuity and fusion &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Testing of accommodation and convergence amplitudes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Central visual field testing (Amsler grid) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pupillometry &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Expanded evaluation of ocular motility and alignment in multiple fields of gaze at distance and near &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exophthalmometry (e.g., Hertel) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tear breakup time &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Schirmer testing and ocular surface dye staining &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Corneal sensation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Gonioscopy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Functional evaluation of the nasolacrimal tear drainage system &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Extended indirect ophthalmoscopy with scleral indentation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Contact lens stereoscopic biomicroscopy (e.g., Goldmann three-mirror lens) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Additional diagnostic testing may include the following:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Analysis of the corneal shape (e.g., keratometry and/or corneal topography) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ocular wavefront analysis (aberrometry) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Measurement of corneal thickness (pachymetry) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Corneal endothelial cell analysis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;External, slit-lamp, or fundus photography &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Anterior and posterior segment imaging (e.g., optical coherence tomography, Scheimpflug photography, high-frequency ultrasound, or confocal microscopy) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Visual fields by automated perimetry &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stereophotography or computer-based image analysis of the optic disc and retinal nerve fiber layer or macula &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ophthalmic ultrasonography &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fluorescein or indocyanine green angiography &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Electrophysiological testing &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Microbiology and cytology &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In-office point-of-care testing (i.e., immunochromatography) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Radiologic testing &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Laboratory tests for systemic disease&amp;nbsp; &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Diagnosis and Management&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The ophthalmologist evaluates and integrates the findings of the comprehensive ophthalmologic examination with all aspects of the patient's health status and social situation in determining an appropriate course of action. Patients are considered in one of three general categories based on the results of the evaluation: patients with no risk factors, patients with risk factors, and patients with conditions that require intervention.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Category I: Patients with No Risk Factors&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;When the initial comprehensive evaluation is normal or involves only optical abnormalities that require corrective lenses, the ophthalmologist reviews the findings with the patient and advises him/her of the appropriate interval for re-examination. Although this category of patients is considered low risk, periodic re-examination is indicated to detect new, potentially asymptomatic, or unrecognized ocular disease, the incidence of which increases with age, such as glaucoma, diabetic retinopathy, and age-related macular degeneration (AMD).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In the absence of symptoms or other indications following the initial comprehensive medical eye evaluation, periodic evaluations are recommended at the frequency indicated in Table 1 below, which takes into account the relationship between increasing age and the risk of asymptomatic or undiagnosed disease. At the time of each comprehensive medical eye evaluation, the ophthalmologist will reassess the patient to determine the appropriate follow-up interval. Adults with no signs or risk factors for eye disease should receive a comprehensive medical eye evaluation at age 40 if they have not previously received one.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Interim evaluations, such as screenings, refractions, or less extensive evaluations, are indicated to address episodic minor problems and complaints or for patient reassurance. Other situations may warrant a comprehensive medical eye evaluation. The extent of the interim evaluation to be performed is determined by the patient's condition and complaints and by the ophthalmologist's medical judgment.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Recommendation Grades&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;em&gt;&lt;strong&gt;Patients 65 or older without risk factors for eye disease should have comprehensive medical eye evaluations at the intervals shown in Table 1&lt;/strong&gt; (Strong recommendation; moderate evidence).&lt;/em&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;em&gt;&lt;strong&gt;Patients under 64 without risk factors for eye disease should have comprehensive medical eye evaluations at the intervals shown in Table 1&lt;/strong&gt; (Discretionary recommendation; insufficient evidence).&lt;/em&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table 1: Comprehensive Medical Eye Evaluation for Adults with No Risk Factors&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table 1: Comprehensive Medical Eye Evaluation for Adults with No Risk Factors&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Age (years)&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Frequency of Evaluation&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;65 or older&lt;sup&gt;1&lt;/sup&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Every 1&amp;ndash;2 years&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;55&amp;ndash;64&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Every 1&amp;ndash;3 years&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;40&amp;ndash;54&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Every 2&amp;ndash;4 years&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Under 40&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;5&amp;ndash;10 years&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;Interim eye evaluations, consisting of vision examinations (refractions, eyeglasses, contact lens evaluations, etc.), may be performed during these periods as well. Patients with risk factors for disease or symptoms and signs of eye disease, and patients who desire an examination, may have additional evaluations during these periods.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Sloan FA, Picone G, Brown DS, Lee PP. Longitudinal analysis of the relationship between regular eye examinations and changes in visual and functional status. J Am Geriatr Soc 2005;53:1867-74. [II+]&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Category II: Patients with Risk Factors&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A patient is considered to be at increased risk when the evaluation reveals signs that are suggestive of a potentially abnormal condition or when risk factors for developing ocular disease are identified but the patient does not yet require intervention. These situations may merit closer follow-up to monitor the patient's ocular health and to detect early signs of disease.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The ophthalmologist determines an appropriate follow-up interval for each patient based on the presence of early signs, risk factors, the incidence of disease, and&amp;nbsp;the potential rate of progression of a given disease. For example, individuals of African descent require more frequent examinations because they are at higher risk for an earlier onset and more rapid progression of glaucoma due to the higher risk in this population. It is recommended that patients with the conditions and risk factors noted in Table 2 (below) undergo a comprehensive medical eye evaluation at the listed intervals.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Recommendation Grades&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;em&gt;&lt;strong&gt;Patients with diabetes mellitus should have comprehensive medical eye evaluations at the intervals shown in Table 2&lt;/strong&gt; (Strong recommendation; moderate evidence).&lt;/em&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;em&gt;&lt;strong&gt;Patients with risk factors for glaucoma should have comprehensive medical eye evaluations at the intervals shown in Table 2&lt;/strong&gt; (Strong recommendation; good evidence).&lt;/em&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table 2: Comprehensive Medical Eye Evaluation for Patients with Diabetes Mellitus or Risk Factors for Glaucoma&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table 2: Comprehensive Medical Eye Evaluation for Patients with Diabetes Mellitus or Risk Factors for Glaucoma&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Condition/Risk Factor&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Frequency of Evaluation*&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Diabetes Mellitus&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Recommended Time&lt;br /&gt;&#xD;&#xA;            of First Examination&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Recommended&lt;br /&gt;&#xD;&#xA;            Follow-up*&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Type 1&lt;sup&gt;1&lt;/sup&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;5 years after onset&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Yearly&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Type 2&lt;sup&gt;2&lt;/sup&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At time of diagnosis&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Yearly&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Prior to pregnancy&lt;sup&gt;3-5&lt;/sup&gt; (Type 1 or 2)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Prior to conception and early in the first trimester&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;See Diabetic Retinopathy Preferred Practice Pattern&lt;sup&gt;&amp;reg;&lt;/sup&gt; (PPP)&lt;sup&gt;6&lt;/sup&gt; for interval recommendations based on findings at first examination.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Condition/Risk Factor&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Frequency of Evaluation*&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Risk Factors for Glaucoma&lt;sup&gt;7-12&lt;/sup&gt;&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Age 65 or older&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Every 6&amp;ndash;12 months&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Age 55&amp;ndash;64&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Every 1&amp;ndash;2 years&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Age 40&amp;ndash;54&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Every 1&amp;ndash;3 years&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;* The ophthalmologist's assessment of degree of risk or abnormal findings may dictate more frequent follow-up examinations.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;1&lt;/sup&gt; Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-6. [II+]&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;2&lt;/sup&gt; Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102:527-32. [II+]&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;3&lt;/sup&gt; Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990;13:34-40. [II+]&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;4&lt;/sup&gt; Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. Diabetes Care 1995;18:631-7. [II+]&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;5&lt;/sup&gt; Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the Diabetes Control and Complications Trial. Diabetes Care 2000;23:1084-91. [II+]&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;6&lt;/sup&gt; American Academy of Ophthalmology Retina Panel. Preferred Practice Pattern Guidelines. Diabetic Retinopathy. San Francisco, CA: American Academy of Ophthalmology; 2008. Available at: &lt;a href=&quot;http://one.aao.org/CE/PracticeGuidelines/PPP.aspx&quot; title=&quot;AAO Web site&quot;&gt;www.aao.org/ppp&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;7&lt;/sup&gt; Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004;122:532-8. [II++]&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;8&lt;/sup&gt; Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-20; discussion 829-30. [I+]&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;9&lt;/sup&gt; Kass MA, Gordon MO, Gao F, et al, Ocular Hypertension Treatment Study Group. Delaying treatment of ocular hypertension: the Ocular Hypertension Treatment Study. Arch Ophthalmol 2010;128:276-87. [I+]&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;10&lt;/sup&gt; Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13; discussion 829-30. [I+]&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;11&lt;/sup&gt; Quigley HA, West SK, Rodriguez J, et al. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol 2001;119:1819-26. [II+]&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;12&lt;/sup&gt; Varma R, Ying-Lai M, Francis BA, et al, Los Angeles Latino Eye Study Group. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology 2004;111:1439-48. [II+]&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Category III: Conditions that Require Interventions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For a patient with ophthalmic or refractive abnormalities, the ophthalmologist prescribes glasses, contact lenses, or other optical devices; treats with medications; arranges for additional evaluation, testing, and follow-up as appropriate; and performs nonsurgical or surgical procedures including laser surgery when indicated.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The ophthalmologist should communicate the examination findings and the need for further evaluation, testing, treatment, or follow-up. Certain findings should be shared with the patient's primary care physician or other specialists, as appropriate. For a patient with systemic abnormalities, the ophthalmologist may advise further evaluation or referral, as appropriate.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Vision rehabilitation restores functional ability, and patients with reduced visual function may be referred for vision rehabilitation and social services. More information on vision rehabilitation, including materials for patients, is available at &lt;a href=&quot;http://www.aao.org/smartsight&quot; title=&quot;AAO Web site&quot;&gt;www.aao.org/smartsight&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Key recommendations for care are defined by GRADE* as follows:&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;5&quot; summary=&quot;Table: Key Recommendations for Care Defined by GRADE&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Strong recommendation&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Used when the desirable effects of an intervention clearly outweigh the undesirable effects or clearly do not.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Discretionary recommendation&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Used when the trade-offs are less certain--either because of low quality evidence or because evidence suggests that desirable and undesirable effects are closely balanced.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 208;336:924-6.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendations for care are formed based on the body of the evidence. The body of evidence quality ratings are defined by GRADE* as follows:&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Body of Evidence Quality Ratings&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Good quality&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is very unlikely to change the confidence in the estimate of effect.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Moderate quality&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is likely to have an important impact on the confidence in the estimate of effect and may change the estimate.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Insufficient quality&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is very likely to have an important impact on the confidence in the estimate of effect and is likely to change the estimate. Any estimate of effect is very uncertain.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 208;336:924-6.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for selected recommendations (see &quot;Major Recommendations&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Preferred Practice Pattern&amp;reg; (PPP) guidelines are based on the best available scientific data as interpreted by panels of knowledgeable health professionals. In some instances, such as when results of carefully conducted clinical trials are available, the data are particularly persuasive and provide clear guidance. In other instances, the panels have to rely on their collective judgment and evaluation of available evidence.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Early recognition, counseling, or treatment may preserve visual function or, in the case of systemic diseases could prevent serious illness or premature death. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Improvement in visual function that occurs as a result of treatment of ocular disorders is accompanied by improvement in life satisfaction, mental health, and home and community activities. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Preferred Practice Pattern&lt;sup&gt;&amp;reg;&lt;/sup&gt; (PPP) guidelines provide the pattern of practice, not for the care of a particular individual.&lt;/strong&gt; While they should generally meet the needs of most patients, they cannot possibly best meet the needs of all patients. Adherence to these PPPs will not ensure a successful outcome in every situation. These practice patterns should not be deemed inclusive of all proper methods of care or exclusive of other methods of care reasonably directed at obtaining the best results. It may be necessary to approach different patients' needs in different ways. The physician must make the ultimate judgment about the propriety of the care of a particular patient in light of all of the circumstances presented by that patient. The American Academy of Ophthalmology is available to assist members in resolving ethical dilemmas that arise in the course of ophthalmic practice. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Preferred Practice Pattern guidelines are not medical standards to be adhered to in all individual situations&lt;/strong&gt;. The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise out of the use of any recommendations or other information contained herein. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;References to certain drugs, instruments, and other products are made for illustrative purposes only and are not intended to constitute an endorsement of such. Such material may include information on applications that are not considered community standard, that reflect indications not included in approved U.S. Food and Drug Administration (FDA) labeling, or that are approved for use only in restricted research settings. The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate patient consent in compliance with applicable law. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American Academy of Ophthalmology Preferred Practice Patterns Committee. Comprehensive adult medical eye evaluation. San Francisco (CA): American Academy of Ophthalmology; 2010. 23 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2000 Sep (revised 2010)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="American Academy of Ophthalmology - Medical Specialty Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;American Academy of Ophthalmology (AAO)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Preferred Practice Patterns Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Preferred Practice Patterns Committee Members&lt;/em&gt;: Christopher J. Rapuano, MD, &lt;em&gt;Chair&lt;/em&gt;; David F. Chang, MD; Emily Y. Chew, MD; Robert S. Feder, MD; Stephen D. McLeod, MD; Bruce E. Prum, Jr., MD; R. Michael Siatkowski, MD; David C. Musch, PhD, MPH, Methodologist&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Academy Staff&lt;/em&gt;: Flora C. Lum, MD; Nancy Collins, RN, MPH; Doris Mizuiri&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The committee members have disclosed the following financial relationships occurring from January 2010 to September 2010:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;David F. Chang, MD: Alcon Laboratories, Inc. &amp;ndash; Consultant/Advisor; Allergan, Inc. &amp;ndash; Lecture fees; Calhoun Vision, Inc. &amp;ndash; Consultant/Advisor, Equity owner; Eyemaginations, Inc. &amp;ndash; Consultant/Advisor, Patent/Royalty; Ista Pharmaceuticals &amp;ndash; Consultant/Advisor, Grant support; LensAR &amp;ndash; Consultant/Advisor; Hoya &amp;ndash; Consultant/Advisor; Revital Vision &amp;ndash; Equity owner; SLACK, Inc. &amp;ndash; Patent/Royalty; Transcend Medical &amp;ndash; Consultant/Advisor&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Emily Y. Chew, MD: No financial relationships to disclose&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Robert S. Feder, MD: Aton Pharma, Inc. &amp;ndash; Consultant/Advisor&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Stephen D. McLeod, MD: Abbott Medical Optics &amp;ndash; Consultant/Advisor, Equity owner; Visiogen, Inc. &amp;ndash; Consultant/Advisor, Equity owner&lt;/p&gt;&#xD;&#xA;&lt;p&gt;David C. Musch, PhD, MPH: Glaukos Corp. &amp;ndash; Consultant/Advisor; MacuSight, Inc. &amp;ndash; Consultant/Advisor; National Eye Institute &amp;ndash; Grant support; NeoVista, Inc. &amp;ndash; Consultant/Advisor; Neurotech USA, Inc. &amp;ndash; Consultant/Advisor; Oraya Therapeutics, Inc. &amp;ndash; Consultant/Advisor; Pfizer Ophthalmics &amp;ndash; Grant support; Washington University &amp;ndash; Grant support&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Bruce E. Prum Jr., MD: Alcon Laboratories, Inc. &amp;ndash; Grant support; Allergan, Inc. &amp;ndash; Consultant/Advisor&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Christopher J. Rapuano, MD: Alcon Laboratories, Inc. &amp;ndash; Lecture fees; Allergan, Inc. &amp;ndash;Consultant/Advisor, Lecture fees; Bausch &amp;amp; Lomb &amp;ndash; Lecture fees; Inspire &amp;ndash; Lecture fees; EyeGate Pharma &amp;ndash; Consultant/Advisor; Inspire &amp;ndash; Lecture fees; Rapid Pathogen Screening &amp;ndash; Equity owner; Vistakon Johnson &amp;amp; Johnson Visioncare, Inc. &amp;ndash; Lecture fees&lt;/p&gt;&#xD;&#xA;&lt;p&gt;R. Michael Siatkowski, MD: National Eye Institute &amp;ndash; Grant support&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Preferred Practice Patterns Committee. Comprehensive adult medical eye evaluation. San Francisco (CA): American Academy of Ophthalmology (AAO); 2005. 15 p. (Preferred practice pattern). [76 references]&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All Preferred Practice Patterns are reviewed by their parent panel annually or earlier if developments warrant and updated accordingly. To ensure that all Preferred Practice Patterns are current, each is valid for 5 years from the &quot;approved by&quot; date unless superseded by a revision.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=64e9df91-dd10-4317-8142-6a87eee7f517&quot; title=&quot;AAO Web site&quot;&gt;American Academy of Ophthalmology (AAO) Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from American Academy of Ophthalmology, P.O. Box 7424, San Francisco, CA 94120-7424; telephone, (415) 561-8540.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This summary was completed by ECRI on June 30, 1998. The information was verified by the guideline developer on December 1, 1998. The summary was updated by ECRI on January 29, 2001. The updated information was verified by the guideline developer on March 12, 2001. This NGC summary was updated by ECRI on January 6, 2006. The updated information was verified by the guideline developer on February 9, 2006. This NGC summary was updated by ECRI Institute on May 13, 2011.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Information about the content, ordering, and copyright permissions can be obtained by calling the American Academy of Ophthalmology at (415) 561-8500.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
